| Name | Title | Contact Details |
|---|
At Neopenda, we believe that the most vulnerable patient populations in the world deserve access to high quality health care. We re a social enterprise startup passionate about improving newborn health through innovative technology solutions, and implementing them sustainably in emerging markets. Neopendas first product is a scalable wireless vital signs monitor for patients in overcrowded, understaffed health facilities. Our solution reduces response time to newborns in distress, and helps healthcare workers to save more lives. We are currently validating our technology in clinical studies with our partners in Uganda.
Health Care System Consultants, Inc is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PhiloMetron Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Formed in 2019, through the merger of Sivantos and Widex, WS Audiology combines more than 140 years experience in pioneering the use of technology to help people with hearing loss hear the sounds that make life wonderful. Today, one out of three hearing aids is made by us and we are active in over 125 markets, employing close to 12,000 people worldwide. Our broad portfolio of leading hearing-related products and services generates annual revenues of more than € 2 billion. WS Audiology is privately owned by the Tøpholm and Westermann families, as well as funds under the management of EQT. As a global leader, our ambition is to unlock human potential by making wonderful sound part of everyone`s life.
At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company`s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area. The Valeda Light Delivery System is CE Marked. The device is not for sale in the USA.